**Equity Swap Contract**

**General Terms**

This Equity Swap Contract is entered into between Party A (Party1) and Party B (Party2) on the Trade Date of 2001-09-24. The contract is governed by the ISDA Master Agreement and the Confirmation.

**Trade Details**

* Trade Identifier: 6234 (Party A) and 6569 (Party B)
* Trade Date: 2001-09-24
* Effective Date: 2001-09-24 (Party A Calculation Period) and 2001-09-24 (Party B Calculation Period)
* Termination Date: 2002-09-24 (Party A) and 2002-09-24 (Party B)

**Product Details**

* Product Type: Equity Swap
* Underlying Security: Shire Pharmaceuticals Group - American Depositary Receipts (SHPGY.O)
* Return Type: Total Return
* Dividend Return Terms: Ex-Dividend, Extraordinary Dividends Party: Party C, Dividend Currency: Determined by Dividend Currency
* Dividend Period: From 2001-09-24 to 2002-09-24

**Payout Terms**

* Party A Payout: Interest Rate Payout (4.427% p.a. on USD Notional Amount)
* Party B Payout: Performance Payout (USD SOFR-COMPOUND p.a. on USD Notional Amount)
* Payout Dates: Annually 2 Business Days after 2001-09-24, commencing on 2001-10-12 and ending on 2002-09-24

**Notional Amount**

* USD Notional Amount: 760400 Shares (Party A) and 28469376 USD (Party B)

**Calculation Agent**

* Calculation Agent: Party C (Calculation Agent Independent)

**Governing Law**

* Governing Law: English

**Documentation**

* Documentation: ISDA

**Risk Disclosure**

* Risk Disclosure: This contract involves significant risks, including foreign exchange risk, price risk, liquidity risk, and credit risk. Parties should consult their own financial, legal, accounting, and tax advisors before entering into this contract.

**Scenario Analysis**

* Scenario 1: USD SOFR-COMPOUND remains unchanged over the tenor of the trade
* Scenario 2: USD SOFR-COMPOUND increases over the tenor of the trade
* Scenario 3: USD SOFR-COMPOUND decreases over the tenor of the trade

**Mark to Market (MTM) Sensitivity Analysis**

* MTM Sensitivity due to parallel shift in USD SOFR-COMPOUND Curve immediately after Trade Date
* MTM Sensitivity due to parallel shift in USD SOFR-COMPOUND Curve as on Mandatory Termination Date compared to Trade Date

**Representations**

* Each party represents to the other party that they are acting for their own account, have made their own independent decisions to enter into this contract, and are capable of assessing the merits and risks of this contract.

**Acceptance**

* This contract is accepted and agreed upon by Party B on behalf of themselves.

Note: The above description is a concise summary of the contract details from the provided CDM representation. It covers all the essential information, including trade details, product details, payout terms, notional amount, calculation agent, governing law, documentation, risk disclosure, scenario analysis, MTM sensitivity analysis, and representations.